Status:
COMPLETED
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
Lead Sponsor:
Vantive Health LLC
Collaborating Sponsors:
University of Louisville
Gambro Renal Products, Inc.
Conditions:
Renal Failure Chronic Requiring Hemodialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
During hemodialysis treatments, patients receive heparin to prevent clotting. The purpose of this pilot study is to determine if the amount of heparin administered during a patient's hemodialysis can ...
Eligibility Criteria
Inclusion
- Adults 18 years of age or older
- Stable hemodialysis prescription prior to study enrollment
- Dialyzing through a native fistula or Gore-Tex graft
- Blood access must be able to provide a blood flow rate of 400 ml/min
Exclusion
- Non-compliance with dialysis
- Hematocrit less than 28%
- Active Infection
- Diagnosis of Heparin-Induced Thrombocytopenia (HIT)
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01181544
Start Date
March 1 2011
End Date
August 1 2011
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Louisville
Louisville, Kentucky, United States, 40202-1718